<p>Table of Content 1. Global Benign Prostatic Hyperplasia Market Introduction and Market Overview 1.1. Objective of the Study 1.2. Global Benign Prostatic Hyperplasia Market Scope and Market Estimation 1.2.1. Global Benign Prostatic Hyperplasia Overall Market Size (US$ Mn), Market CAGR (%), Market forecast (2022-2030) 1.2.2. Global Benign Prostatic Hyperplasia Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2022-2030 1.3. Market Segmentation 1.3.1. Product of Global Benign Prostatic Hyperplasia Market 1.3.2. Therapy of Global Benign Prostatic Hyperplasia Market 1.3.3. Region of Global Benign Prostatic Hyperplasia Market 2. Global Benign Prostatic Hyperplasia Market - Executive Summary 2.1. Key Findings 2.1.1. Top Impacting Factors 2.1.2. Top Investment Pockets 2.1.3. Market Attractiveness Analysis 2.2. Key Companies Introduction 3. Market Factor Analysis 3.1. Global Benign Prostatic Hyperplasia Market Industry Development Trends under COVID-19 Outbreak 3.1.1. Global COVID-19 Status Overview 3.1.2. Influence of COVID-19 Outbreak on Global Benign Prostatic Hyperplasia Market Industry Development 3.2. Market Dynamics (Growth Influencers) 3.2.1. Drivers 3.2.2. Restraints 3.2.3. Opportunities 3.2.4. Impact Analysis of Drivers and Restraints 3.3. Ecosystem/ Value Chain Analysis 3.4. Porter’s Five Forces Analysis 3.5. SWOT Analysis 3.6. PEST Analysis 3.7. Market Opportunity Assessment – by Region (North America/ Europe/ Asia Pacific/ Middle East and Africa/ South America) 3.7.1. By Product 3.7.2. By Therapy 4. Global Benign Prostatic Hyperplasia Market: Estimates & Historic Trend Analysis (2018-2020) 5. Global Benign Prostatic Hyperplasia Market Estimates & Forecast Trend Analysis, by Product 5.1. Benign Prostatic Hyperplasia Market Share (%) Estimates and Forecasts, by Product, 2022 & 2030 5.1.1. Key Market Trends, Growth Factors, and Opportunities 5.1.2. Alpha blocker 5.1.3. 5-Alpha reductase inhibitor 5.1.4. Phosphodiesterase-5 inhibitor 5.1.5. Others 5.2. Benign Prostatic Hyperplasia Market Revenue (US$ Mn) Estimates and Forecasts, by Product, 2018 to 2030 6. Global Benign Prostatic Hyperplasia Market Estimates & Forecast Trend Analysis, by Therapy 6.1. Benign Prostatic Hyperplasia Market Share (%) Estimates and Forecasts, by Therapy, 2022 & 2030 6.1.1. Key Market Trends, Growth Factors, and Opportunities 6.1.2. Mono Drug Therapy 6.1.3. Combination Drug Therapy 6.2. Benign Prostatic Hyperplasia Market Revenue (US$ Mn) Estimates and Forecasts, by Therapy, 2018 to 2030 7. Global Benign Prostatic Hyperplasia Market Analysis and Forecast, by Region 7.1. Benign Prostatic Hyperplasia Market Share (%) Estimates and Forecasts, by Region, 2022 & 2030 7.1.1. North America 7.1.2. Europe 7.1.3. Asia Pacific 7.1.4. Middle East and Africa 7.1.5. South America 7.2. Benign Prostatic Hyperplasia Market Revenue (US$ Mn) Estimates and Forecasts, by Region, 2018 to 2030 8. North America Benign Prostatic Hyperplasia Market: Estimates & Forecast Trend Analysis 8.1. North America Market Assessments & Key Findings 8.2. North America Benign Prostatic Hyperplasia Market Share (%) Estimates and Forecasts, 2022 & 2030 8.3. North America Benign Prostatic Hyperplasia Market Size Estimates and Forecast (US$ Million) (2018 to 2030) 8.3.1. By Product 8.3.2. By Therapy 8.3.3. By Country 8.3.3.1. U.S. 8.3.3.2. Canada 8.3.3.3. Mexico 9. Europe Benign Prostatic Hyperplasia Market: Estimates & Forecast Trend Analysis 9.1. Europe Market Assessments & Key Findings 9.2. Europe Benign Prostatic Hyperplasia Market Share (%) Estimates and Forecasts, 2022 & 2030 9.3. Europe Benign Prostatic Hyperplasia Market Size Estimates and Forecast (US$ Million) (2018 to 2030) 9.3.1. By Product 9.3.2. By Therapy 9.3.3. By Country 9.3.3.1. Germany 9.3.3.2. U.K. 9.3.3.3. France 9.3.3.4. Italy 9.3.3.5. Spain 9.3.3.6. Russia 9.3.3.7. Rest of Europe 10. Asia Pacific Benign Prostatic Hyperplasia Market: Estimates & Forecast Trend Analysis 10.1. Asia Pacific Market Assessments & Key Findings 10.2. Asia Pacific Benign Prostatic Hyperplasia Market Share (%) Estimates and Forecasts, 2022 & 2030 10.3. Asia Pacific Market Size Estimates and Forecast (US$ Million) (2018 to 2030) 10.3.1. By Product 10.3.2. By Therapy 10.3.3. By Country 10.3.3.1. China 10.3.3.2. Japan 10.3.3.3. India 10.3.3.4. Australia 10.3.3.5. South Korea 10.3.3.6. Rest of Asia Pacific 11. South America Benign Prostatic Hyperplasia Market: Estimates & Forecast Trend Analysis 11.1. South America Market Assessments & Key Findings 11.2. South America Benign Prostatic Hyperplasia Market Share (%) Estimates and Forecasts, 2022 & 2030 11.3. South America Market Size Estimates and Forecast (US$ Million) (2018 to 2030) 11.3.1. By Product 11.3.2. By Therapy 11.3.3. By Country 11.3.3.1. Brazil 11.3.3.2. Argentina 11.3.3.3. Colombia 11.3.3.4. Rest of South America 12. Middle East & Africa Benign Prostatic Hyperplasia Market: Estimates & Forecast Trend Analysis 12.1. Middle East & Africa Market Assessments & Key Findings 12.2. Middle East & Africa Benign Prostatic Hyperplasia Market Share (%) Estimates and Forecasts, 2022 & 2030 12.3. Middle East & Africa Market Size Estimates and Forecast (US$ Million) (2018 to 2030) 12.3.1. By Product 12.3.2. By Therapy 12.3.3. By Country 12.3.3.1. U.A.E. 12.3.3.2. Saudi Arabia 12.3.3.3. Egypt 12.3.3.4. South Africa 12.3.3.5. Rest of Middle East & Africa 13. Competition Landscape 13.1. Market Competition Matrix, by Leading Players 13.2. List of Emerging, Prominent and Leading Players 13.3. Major Mergers & Acquisitions, Partnership, Joint Venture, Expansions, Deals, Etc. 14. Company Profiles 14.1. Boston Scientific Corporation 14.1.1. Company Overview 14.1.2. Financial Performance 14.1.3. Product Portfolio 14.1.4. Geographical Footprint 14.1.5. Strategic Initiatives 14.1.6. SWOT Analysis 14.2. Coloplast Group 14.2.1. Company Overview 14.2.2. Financial Performance 14.2.3. Product Portfolio 14.2.4. Geographical Footprint 14.2.5. Strategic Initiatives 14.2.6. SWOT Analysis 14.3. Teleflex Incorporated 14.3.1. Company Overview 14.3.2. Financial Performance 14.3.3. Product Portfolio 14.3.4. Geographical Footprint 14.3.5. Strategic Initiatives 14.3.6. SWOT Analysis 14.4. Olympus Corporation 14.4.1. Company Overview 14.4.2. Financial Performance 14.4.3. Product Portfolio 14.4.4. Geographical Footprint 14.4.5. Strategic Initiatives 14.4.6. SWOT Analysis 14.5. GlaxoSmithKline PLC 14.5.1. Company Overview 14.5.2. Financial Performance 14.5.3. Product Portfolio 14.5.4. Geographical Footprint 14.5.5. Strategic Initiatives 14.5.6. SWOT Analysis 14.6. Eli Lilly 14.6.1. Company Overview 14.6.2. Financial Performance 14.6.3. Product Portfolio 14.6.4. Geographical Footprint 14.6.5. Strategic Initiatives 14.6.6. SWOT Analysis 14.7. Pfizer, Inc. 14.7.1. Company Overview 14.7.2. Financial Performance 14.7.3. Product Portfolio 14.7.4. Geographical Footprint 14.7.5. Strategic Initiatives 14.7.6. SWOT Analysis 14.8. Abbott 14.8.1. Company Overview 14.8.2. Financial Performance 14.8.3. Product Portfolio 14.8.4. Geographical Footprint 14.8.5. Strategic Initiatives 14.8.6. SWOT Analysis 14.9. Asahi Kasei Corporation 14.9.1. Company Overview 14.9.2. Financial Performance 14.9.3. Product Portfolio 14.9.4. Geographical Footprint 14.9.5. Strategic Initiatives 14.9.6. SWOT Analysis 14.10. Merck & Co., Inc. 14.10.1. Company Overview 14.10.2. Financial Performance 14.10.3. Product Portfolio 14.10.4. Geographical Footprint 14.10.5. Strategic Initiatives 14.10.6. SWOT Analysis 14.11. Astellas Pharma Inc. 14.11.1. Company Overview 14.11.2. Financial Performance 14.11.3. Product Portfolio 14.11.4. Geographical Footprint 14.11.5. Strategic Initiatives 14.11.6. SWOT Analysis 14.12. Allergan plc 14.12.1. Company Overview 14.12.2. Financial Performance 14.12.3. Product Portfolio 14.12.4. Geographical Footprint 14.12.5. Strategic Initiatives 14.12.6. SWOT Analysis 14.13. Alembic 14.13.1. Company Overview 14.13.2. Financial Performance 14.13.3. Product Portfolio 14.13.4. Geographical Footprint 14.13.5. Strategic Initiatives 14.13.6. SWOT Analysis 14.14. IPG Photonics Corporation 14.14.1. Company Overview 14.14.2. Financial Performance 14.14.3. Product Portfolio 14.14.4. Geographical Footprint 14.14.5. Strategic Initiatives 14.14.6. SWOT Analysis 14.15. Richard Wolf GmbH 14.15.1. Company Overview 14.15.2. Financial Performance 14.15.3. Product Portfolio 14.15.4. Geographical Footprint 14.15.5. Strategic Initiatives 14.15.6. SWOT Analysis 14.16. Unilab, Inc. 14.16.1. Company Overview 14.16.2. Financial Performance 14.16.3. Product Portfolio 14.16.4. Geographical Footprint 14.16.5. Strategic Initiatives 14.16.6. SWOT Analysis 14.17. Pharex Health Corporation 14.17.1. Company Overview 14.17.2. Financial Performance 14.17.3. Product Portfolio 14.17.4. Geographical Footprint 14.17.5. Strategic Initiatives 14.17.6. SWOT Analysis 14.18. Biolitec AG 14.18.1. Company Overview 14.18.2. Financial Performance 14.18.3. Product Portfolio 14.18.4. Geographical Footprint 14.18.5. Strategic Initiatives 14.18.6. SWOT Analysis 14.19. Urologix 14.19.1. Company Overview 14.19.2. Financial Performance 14.19.3. Product Portfolio 14.19.4. Geographical Footprint 14.19.5. Strategic Initiatives 15. Assumptions and Research Methodology 16. Conclusions and Recommendations 16.1. Analysis and Suggestions on New Project Investment 16.2. Research Findings and Conclusion List of Tables Table1 Global Benign Prostatic Hyperplasia Market Historic Analysis (US$ Mn), 2018-2021 Table2 Global Benign Prostatic Hyperplasia Market Forecast Opportunity Analysis (US$ Mn), 2022-2030 Table3 Global Benign Prostatic Hyperplasia Market Absolute $ Opportunity Table4 Global Benign Prostatic Hyperplasia Market Analysis by Product, 2018-2030 Table5 Global Benign Prostatic Hyperplasia Market Analysis by Therapy, 2018-2030 Table6 Global Benign Prostatic Hyperplasia Market Analysis by Region, 2018-2030 Table7 North America Benign Prostatic Hyperplasia Market Absolute $ Opportunity Table8 North America Benign Prostatic Hyperplasia Market Analysis by Product, 2018-2030 Table9 North America Benign Prostatic Hyperplasia Market Analysis by Therapy, 2018-2030 Table10 North America Benign Prostatic Hyperplasia Market Analysis by Country, 2018-2030 Table11 Europe Benign Prostatic Hyperplasia Market Absolute $ Opportunity Table12 Europe Benign Prostatic Hyperplasia Market Analysis by Product, 2018-2030 Table13 Europe Benign Prostatic Hyperplasia Market Analysis by Therapy, 2018-2030 Table14 Europe Benign Prostatic Hyperplasia Market Analysis by Country, 2018-2030 Table15 Asia Pacific Benign Prostatic Hyperplasia Market Absolute $ Opportunity Table16 Asia Pacific Benign Prostatic Hyperplasia Market Analysis by Product, 2018-2030 Table17 Asia Pacific Benign Prostatic Hyperplasia Market Analysis by Therapy, 2018-2030 Table18 Asia Pacific Benign Prostatic Hyperplasia Market Analysis by Country, 2018-2030 Table19 South America Benign Prostatic Hyperplasia Market Absolute $ Opportunity Table20 South America Benign Prostatic Hyperplasia Market Analysis by Product, 2018-2030 Table21 South America Benign Prostatic Hyperplasia Market Analysis by Therapy, 2018-2030 Table22 South America Benign Prostatic Hyperplasia Market Analysis by Country, 2018-2030 Table23 MEA Benign Prostatic Hyperplasia Market Absolute $ Opportunity Table24 MEA Benign Prostatic Hyperplasia Market Analysis by Product, 2018-2030 Table25 MEA Benign Prostatic Hyperplasia Market Analysis by Therapy, 2018-2030 Table26 MEA Benign Prostatic Hyperplasia Market Analysis by Country, 2018-2030 List of Figures Figure1 Global Benign Prostatic Hyperplasia Market Historic Y-o-Y Analysis (%), 2018-2021 Figure2 Global Benign Prostatic Hyperplasia Market Forecast Y-o-Y Analysis (%), 2022-2030 Figure3 Global Benign Prostatic Hyperplasia Market Share Analysis by Product, 2021 and 2030 Figure4 Global Benign Prostatic Hyperplasia Market Share Analysis by Therapy, 2021 and 2030 Figure5 Global Benign Prostatic Hyperplasia Market Share Analysis by Region, 2021 and 2030 Figure6 North America Benign Prostatic Hyperplasia Market Share Analysis by Product, 2021 and 2030 Figure7 North America Benign Prostatic Hyperplasia Market Share Analysis by Therapy, 2021 and 2030 Figure8 North America Benign Prostatic Hyperplasia Market Share Analysis by Country, 2021 and 2030 Figure9 South America Benign Prostatic Hyperplasia Market Share Analysis by Product, 2021 and 2030 Figure10 South America Benign Prostatic Hyperplasia Market Share Analysis by Therapy, 2021 and 2030 Figure11 South America Benign Prostatic Hyperplasia Market Share Analysis by Country, 2021 and 2030 Figure12 Europe Benign Prostatic Hyperplasia Market Share Analysis by Product, 2021 and 2030 Figure13 Europe Benign Prostatic Hyperplasia Market Share Analysis by Therapy, 2021 and 2030 Figure14 Europe Benign Prostatic Hyperplasia Market Share Analysis by Country, 2021 and 2030 Figure15 Asia Pacific Benign Prostatic Hyperplasia Market Share Analysis by Product, 2021 and 2030 Figure16 Asia Pacific Benign Prostatic Hyperplasia Market Share Analysis by Therapy, 2021 and 2030 Figure17 Asia Pacific Benign Prostatic Hyperplasia Market Share Analysis by Country, 2021 and 2030 Figure18 MEA Benign Prostatic Hyperplasia Market Share Analysis by Product, 2021 and 2030 Figure19 MEA Benign Prostatic Hyperplasia Market Share Analysis by Therapy, 2021 and 2030 Figure20 MEA Benign Prostatic Hyperplasia Market Share Analysis by Country, 2021 and 2030</p>